Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;118(8-9):497-507.
doi: 10.1016/j.acvd.2025.05.003. Epub 2025 May 29.

Safety and efficacy of transcatheter correction of sinus venosus defect using 70-100mm-long partially covered Optimus-CVS® XXL stents compared with surgery: The OPTIVENOSUS study design

Affiliations

Safety and efficacy of transcatheter correction of sinus venosus defect using 70-100mm-long partially covered Optimus-CVS® XXL stents compared with surgery: The OPTIVENOSUS study design

Clément Batteux et al. Arch Cardiovasc Dis. 2025 Sep.

Abstract

Background: Transcatheter correction of sinus venosus defect provides a less invasive alternative to open-heart surgery.

Aim: To evaluate the safety and efficacy of 70-100mm-long partially covered balloon-expandable Optimus-CVS® XXL stents (AndraTec, Koblenz, Germany), specifically designed for sinus venosus defect repair, compared with surgical intervention.

Methods: OPTIVENOSUS is a French nationwide multicentre prospective comparative cohort study of patients with indications for sinus venosus defect correction (May 2023 to February 2031). The study comprises two parts, with a comprehensive shift in patient assignment to the catheter group. Part 1 will enrol 30 adult patients (aged>18years) deemed ineligible for surgery by a multidisciplinary team, who will undergo feasibility assessment for catheter correction, including virtual simulations and three-dimensional-printed bench testing. Part 2 will add 30 adult patients with favourable anatomy, considered directly for stent therapy, whereas three-dimensional-printed bench testing will be reserved for complex cases. Surgical patients (aged ≥12years) will be enrolled continuously throughout the study, with no enrolment cap. All patients will receive standardized follow-up for up to 5years.

Results: The primary endpoint is a 6-month composite measure of safety and efficacy, defined by trivial or absent residual shunt and the absence of major adverse events (death or surgical conversion). If no significant difference is found, efficacy (end-diastolic right ventricular volume reduction) and safety (absence of reintervention, stroke, pacemaker implantation or severe arrhythmia) will be further evaluated using hierarchical analysis.

Conclusion: The OPTIVENOSUS study evaluates the safety and effectiveness of transcatheter sinus venosus defect correction with Optimus-CVS® XXL stents versus surgery (NCT05865119).

Keywords: Catheterization; Congenital heart disease; Covered stent; Sinus venosus defect.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest The authors declare that they have no competing interest.

Publication types

MeSH terms

Supplementary concepts

Associated data